Skip to main content

Markerstudy "keen to get back on the acquisition drug" after £200m investment

Gary Humphreys Markerstudy

Group underwriting director Gary Humphreys says funding agreement led by Pollen Street Capital restructures the MGA's debt and opens the business up for making further deals.

Markerstudy is hoping to make an acquisition in the UK in the first quarter of this year, according to group underwriting director Gary Humphreys.

It was revealed earlier this week that the provider had secured a £200m investment deal led by Pollen Street Capital.

Humphreys told Insurance Age that the managing general agent had been looking for external investment for some time, adding “we’d got to the stage where the group was of such a size that running it from personal funding was limiting

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@insuranceage.co.uk or view our subscription options here: https://subscriptions.insuranceage.co.uk/subscribe

You are currently unable to copy this content. Please contact info@insuranceage.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Age? View our subscription options

Register

Sign up and gain access to five complimentary news articles every month.

Already have an account? Sign in here

Show password
Hide password

End of Year Review 2025: Ecclesiastical’s David Carey

David Carey, managing director of Ecclesiastical’s intermediary business applauds the £10m landmark reached by Insurance United Against Dementia, cautions against a one dimensional approach to risk pricing; and gets misty eyed about ‘Madchester’.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Age account, please register now.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: